Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.

Loading...
Thumbnail Image

Embargo End Date

Authors

Mackay, A
Burford, A
Carvalho, D
Izquierdo, E
Fazal-Salom, J
Taylor, KR
Bjerke, L
Clarke, M
Vinci, M
Nandhabalan, M
Temelso, S
Popov, S
Molinari, V
Raman, P
Waanders, AJ
Han, HJ
Gupta, S
Marshall, L
Zacharoulis, S
Vaidya, S
Mandeville, HC
Bridges, LR
Martin, AJ
Al-Sarraj, S
Chandler, C
Ng, H-K
Li, X
Mu, K
Trabelsi, S
Brahim, DH-B
Kisljakov, AN
Konovalov, DM
Moore, AS
Carcaboso, AM
Sunol, M
de Torres, C
Cruz, O
Mora, J
Shats, LI
Stavale, JN
Bidinotto, LT
Reis, RM
Entz-Werle, N
Farrell, M
Cryan, J
Crimmins, D
Caird, J
Pears, J
Monje, M
Debily, M-A
Castel, D
Grill, J
Hawkins, C
Nikbakht, H
Jabado, N
Baker, SJ
Pfister, SM
Jones, DTW
Fouladi, M
von Bueren, AO
Baudis, M
Resnick, A
Jones, C

Document Type

Journal Article

Date

2017-10-09

Date Accepted

2017-08-29

Abstract

We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases. We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors. Genomic aberrations increase with age, highlighting the infant population as biologically and clinically distinct. Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the molecular diversity of the disease, opening up avenues for biological study and providing a basis for functionally defined future treatment stratification.

Citation

Cancer cell, 2017, 32 (4), pp. 520 - 537.e5

Source Title

Publisher

CELL PRESS

ISSN

1535-6108

eISSN

1878-3686

Research Team

Glioma Team
Paediatric and Adolescent Radiotherapy

Notes